Extavia (interferon beta-1b) is created from human proteins. Interferons facilitate the body fight infective agentinfections.
Extavia is employed to treat reverting sclerosis (MS). This medication won’t cure MS, it’ll solely decrease the frequency of relapse symptoms.
Extavia may be used for functions unlisted during this medication guide.
Submit your review
Get emergency medical help if you have signs of an allergic reaction to Extavia: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Some patients using interferon medicines have become very depressed or had thoughts of suicide. Stop using Extavia if you have symptoms of depression (sadness, crying, loss of interest in things you once liked) or if you have any thoughts of hurting yourself.
Stop using Extavia and call your doctor at once if you have:
pain, swelling, redness, or skin changes where an injection was given;
pale skin, easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
kidney problems - blood in your urine, swelling or rapid weight gain, little or no urination;
signs of a serious blood cell disorder - confusion, feeling tired or irritable, stomach pain, bloody diarrhea, vomiting;
heart problems - fast heartbeats, shortness of breath (especially when lying down), tight feeling in your chest, swelling in your ankles, rapid weight gain;
liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
low white blood cell counts - fever, chills, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough.
Common Extavia side effects may include:
sleep problems (insomnia);
muscle pain or stiffness;
abnormal liver function tests;
flu symptoms; or
skin reaction where the medicine was injected.
Usual Adult Dose of Extavia for Multiple Sclerosis: Initial dose: 0.0625 mg subcutaneously every other day, and increased (in 25% increments) every 2 weeks, over a 6 week period, to maintenance dose Maintenance dose: 0.25 mg subcutaneously every other day Schedule for dose titration: Weeks 1 and 2: 0.0625 mg subcutaneously every other day (25% of recommended dose) Weeks 3 and 4: 0.125 mg subcutaneously every other day (50% of recommended dose) Weeks 5 and 6: 0.1875 mg subcutaneously every other day (75% of recommended dose) Week 7 and beyond: 0.25 mg subcutaneously every other day (100% of recommended dose)